Начало・Списък с акции・Roivant Sciences Ltd

Roivant Sciences Ltd

Затворен

СекторЗдравеопазване

34.58 0.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.24

Максимум

35.5

Ключови измерители
By Trading Economics
Приходи	669M 356M
Продажби	521K 2.5M
Марж на печалбата	14,116.825
Служители	721
EBITDA	744M 455M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+5.84% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.9B 24B
Предишно отваряне	34.32
Предишно затваряне	34.58

Настроения в новините

By Acuity

50%

175 / 340 Класиране в Healthcare

Roivant Sciences Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 20:02 ч. UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3.08.2026 г., 20:06 ч. UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

31.07.2026 г., 20:02 ч. UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

30.07.2026 г., 23:46 ч. UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

29.07.2026 г., 23:02 ч. UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

28.07.2026 г., 23:06 ч. UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

24.07.2026 г., 18:46 ч. UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

23.07.2026 г., 20:06 ч. UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

22.07.2026 г., 22:26 ч. UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

21.07.2026 г., 22:21 ч. UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

20.07.2026 г., 16:36 ч. UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Сравнение с други в отрасъла

Ценова промяна

Roivant Sciences Ltd Прогноза

Ценова цел

By TipRanks

5.84% нагоре

12-месечна прогноза

Среден 36.61 USD 5.84%

Висок 42 USD

Нисък 29.29 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Roivant Sciences Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Roivant Sciences Ltd през последните 3 месеца.

Настроение

By Acuity

175 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.